

Leaps by Bayer, Khloris to develop breakthrough anti-cancer vaccines

03 April 2019 | News | By Manbeena Chawla

Seed investment of Leaps by Bayer paves an exclusive leadership position for next generation oncology business



Leaps by Bayer, the investment arm of the global life sciences company Bayer, and Khloris Biosciences, a biotechnology company, have announced that they have joined forces to develop novel, first-in-class anti-cancer vaccines based on human induced pluripotent stem cells (iPSCs).

This technology has the potential to address one of today's biggest issues in human health: to prevent and cure cancer.

Human iPSCs have potential as anti-cancer vaccines because they share the same characteristics of cancer cells, such as expression of tumor antigens and the ability to self-renew. Injecting iPSCs that genetically match the recipient, but that are unable to replicate, can safely expose the immune system to a variety of cancer-specific targets.

"Bayer's development expertise, commercial reach and worldwide network of R&D sites, combined with our scientific knowledge and technology, will increase the chances to bring this potential breakthrough option to patients in need," commented Prof. Joseph C. Wu, a co-founder of Khloris.

"This alliance is in line with our passion for developing truly innovative and disruptive cancer therapies that have a major and lasting impact on disease. Leaps by Bayer offered a unique investment concept that allows big ideas to flourish," stated Dr. Lynne A. Bui, co-founder and CEO of Khloris.